Additionally, heat-shock protein 90 (HSP90) and BCL-2 inhibitors (e.g. XL888 and Obatoclax) were selected alongside cardiac glycosides (such as Lanatoside C, Proscillaridin A), inhibiting the Na+/K + ATPase pump, which represent an emerging therapeutic target in cancer [20, 21]. This evidence concerns the gene BCL2 and cancer.